Delving into the Latest Updates on Chlorhexidine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CHX, Chlorhexidine hydrochloride (JP17/USP), 洗必泰

+ [3]

Target-

Mechanism

Cell membrane function inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication

Burn infectionsWound Infection

Inactive Indication-

Originator Organization-

Active Organization

Bayer Australia Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (05 Dec 2006),

Burn infectionsWound Infection

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H31Cl3N10

InChIKeyAVRXPIQGQAHQTQ-UHFFFAOYSA-N

CAS Registry3697-42-5

Comparing between different intracanal medications with different combination forms of Modified Triple Antibiotic Paste, Calcium Hydroxide and Chlorehexidine, regarding antimicrobial efficacy through bacterial reduction count of enterococcus Faecalis and regarding clinical and radiographic success in non vital primary teeth necessitating pulpectomy with follow up time 1 year.

Start Date01 Jan 2025

Sponsor / Collaborator

Cairo University

NCT06738342

/ Not yet recruitingNot ApplicableIIT

Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara in Patients Undergoing Periodontal Surgery: a Triple-blind, Parallel-arm, Randomized Controlled Trial

The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.

Start Date01 Dec 2024

Sponsor / Collaborator

Sapienza University of Rome

100 Clinical Results associated with Chlorhexidine Hydrochloride

Login to view more data

100 Translational Medicine associated with Chlorhexidine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Chlorhexidine Hydrochloride

Login to view more data

10,027

Literatures (Medical) associated with Chlorhexidine Hydrochloride

01 Feb 2025·Poultry Science

Research Note: Evaluation of selected chlorhexidine salts/product and/or cetylpyridinium chloride as potential pre-slaughter crop disinfection agents using an in vitro assay simulating crop contents

Article

Author: Hargis, B M ; Latorre, J D ; Martin, K ; Laverty, L M

Salmonellae remain a prominent issue for poultry products regarding food safety. A predominant source of broiler carcass contamination at processing is from crop rupturing and subsequent contamination of the carcass during evisceration. Chlorhexidine (CHX) salts are commonly used in dental products for their antimicrobial capabilities. We evaluated CHX gluconate and CHX digluconate alongside cetylpyridinium chloride (CPC), a common disinfectant to test their antimicrobial properties and any possible synergistic effects between the two. These effects were evaluated using an in vitro assay simulating the crop contents of poultry. CHX digluconate, CHX gluconate, commercially available CHX gluconate and CPC were tested at 0.1 %, 0.2 %, 1 %, 1.8 %, and 2 %. Borosilicate tubes containing 2.5 g of chicken mash feed, pasteurized to remove unwanted bacteria, were used for assay. Pasteurized feed within tubes were suspended in CHX, CPC, CHX + CPC, or saline vehicle alone (control). Tubes were then inoculated with Salmonella Typhimurium (ST) (except non-inoculated controls) and allowed to statically incubate for 2 h at 37°C. Tube contents were then serially diluted for CFU enumeration. CHX and CPC, when used individually, demonstrated meaningful and significant (p < 0.05) reduction in ST recovery, especially at higher concentrations (1-2 %). Combinations of CHX + CPC at lower concentrations (0.1-0.2 %) were shown to have major antimicrobial effects and either reduced (p < 0.05) or eliminated ST recovery in this assay. These lower concentrations might be used for antemortem disinfection of crop contents prior to live haul at processing in future studies. In vivo efficacy may be affected by limitations on voluntary ingestion of drinking water during pre-slaughter feed withdrawal and was not evaluated in these studies.

01 Feb 2025·Clinical Microbiology and Infection

Eradication of community-onset Methicillin-resistant Staphylococcus aureus carriage: a narrative review

Review

Author: de Boer, Mark G J ; Lambregts, Merel M C ; Hanssen, Jaap L J ; Westgeest, Annette C ; Schippers, Emile F

BACKGROUNDMethicillin-resistant Staphylococcus aureus (MRSA) colonization increases infection risk in both patients and healthy individuals. Decolonization therapy has been proven to reduce S. aureus infections, but data on the effectiveness of individual decolonization strategies in community-onset MRSA carriage are scarce.OBJECTIVESThe aim of this narrative review was to summarize the evidence on strategies for the elimination of MRSA colonization in community-onset MRSA carriers.SOURCESPubMed database was searched for studies on MRSA eradication, from inception to July 2023.CONTENTTopical therapy is proven to be effective in nasal-only carriage and in temporary load reduction. Mupirocin nasal ointment in combination with chlorhexidine body wash is highly effective in nasal-only MRSA carriers in the community as well. In patients with extra-nasal colonization, addition of orally administered antibiotics likely increases success rates compared with topical therapy alone. Studies on systemic treatment of extra-nasal MRSA decolonization are subject to a high heterogeneity of antimicrobial agents, treatment duration, and control groups. The majority of evidence supports the use of a combination of topical therapy with rifampin and another antimicrobial agent. Decolonization treatment with probiotics is a promising novel non-antibiotic strategy. However, achieving long-term decolonization is more likely in countries with low MRSA prevalence, given the risk of recolonization in a context of high MRSA prevalence.IMPLICATIONSThe decision to pursue community-onset MRSA eradication treatment in the individual patient should be based on the combination of the treatment objective (short-term bacterial load reduction in health care settings vs. long-term eradication in community settings), and the likelihood of successful decolonization. The latter is influenced by both individual risk factors for treatment failure, and the risk of recolonization. The addition of a combination of systemic antibiotics is rational for extra-nasal long-term decolonization. To determine the most effective systemic antimicrobial agents in MRSA decolonization, more research is needed.

01 Feb 2025·Journal of Allergy and Clinical Immunology: Global

Stability of diluted chlorhexidine for skin testing in drug allergy evaluations

Article

Author: Volcheck, Gerald W ; Garvey, Lene H ; Shah, Divya ; Gonzalez-Estrada, Alexei ; Cojuc-Konigsberg, Gabriel ; Chiarella, Sergio E ; Kita, Hirohito ; Brown, Stacy D

BackgroundChlorhexidine gluconate (CHX), a common cause of perioperative anaphylaxis, is frequently used for skin testing in allergy evaluations. Although CHX's maximal nonirritating concentrations are known, the stability of its dilutions for skin testing remains unexplored, particularly when sterile water for injection (SWFI) or normal saline (NS) are used as diluents.ObjectiveOur aim was to evaluate the stability and precipitation of CHX when diluted with SWFI or NS for drug allergy skin testing.MethodsCHX dilutions (5-0.002 mg/mL) were prepared using SWFI and NS. HPLC and UV-visible spectrophotometry were used to assess stability and precipitation over 48 hours. Turbidity was measured at various time points to monitor precipitation.ResultsHPLC analysis showed no significant differences in peak heights between CHX-SWFI and CHX-NS dilutions. However, visible precipitation and increased turbidity (>100 NTU) were observed in CHX-NS at higher concentrations (5 mg/mL) after 60 minutes. No precipitation occurred in CHX-SWFI at any concentration for 48 hours.ConclusionFor CHX skin testing, SWFI is the preferred diluent at concentrations higher than 0.02 mg/mL to avoid precipitation. Using NS for the final dilution from 0.02 to 0.002 mg/mL is feasible and reduces injection pain. Except for CHX-NS at 5 mg/mL, reagents can be prepared up to 24 hours before testing.

100 Deals associated with Chlorhexidine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01345	-	-	DB00878

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Burn infections	AU	Bayer Australia Ltd.	05 Dec 2006
Wound Infection	AU	Bayer Australia Ltd.	05 Dec 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03503370 (CTgov)	Phase 2	Diabetic foot ulcer	175	Chlorhexidine (Chlorhexidine)	qhaxhaszqt(dxkmvtvmsv) = runcfflmeb nquglfsogt (nhibpkqmgs, zqxtyugusw - jlreancqnr) View more	-	09 Aug 2024
				Placebo (Placebo)	qhaxhaszqt(dxkmvtvmsv) = wstvfypezb nquglfsogt (nhibpkqmgs, pqjjtmkyck - yryurmbinu) View more
WCD2023	Not Applicable	-	-	Chlorhexidine Gentle hand wash (Microshield®)	(yksbclxqtg) = czeyxjpqhs upzytnjtwr (innkilghvt )	-	03 Jul 2023
				Chlorhexidine Gentle hand wash (Gentle wash)	(yksbclxqtg) = qkflcrpolo upzytnjtwr (innkilghvt )
NCT01079663 (CTgov)	Phase 2	Peri-Implantitis	60	Chlorhexidine 2.5 mg (Chlorhexidine Chip (Periochip®))	rhmmywxxvf(etxveprujg) = pbsatbutux ebwvnsivhe (zeqdvemtmo, cjzeoqgrmp - ztuitvnakd) View more	-	15 Jun 2021
				Placebo chip (Placebo Chip)	rhmmywxxvf(etxveprujg) = zsijiywfox ebwvnsivhe (zeqdvemtmo, aswrxnhydq - hjenfuofvh) View more
NCT02252588 (CLIMB, CTgov)	Phase 2	Pulmonary Disease, Chronic Obstructive	44	Placebo+Chlorhexidine (Chlorhexidine)	zjhluqfakt(zmylmpzwgc) = rzllqjxqjf upmjzzerjg (wosbqgrdqi, ujenmndtwo - qyykvqtxuj) View more	-	29 Dec 2020
				Placebo+Chlorhexidine (Placebo)	zjhluqfakt(zmylmpzwgc) = qdfdujhvyt upmjzzerjg (wosbqgrdqi, vocmbnmftv - woajeahxzv) View more
NCT03412734 (CTgov)	Phase 4	-	94	Chlorhexidine (Chlorhexidine Group)	tuzuqzghis(gftruhpmgh) = gmvkqmttcn fgqivhzjvx (reuahppoze, tvwpmcwbah - qcmkwcjpbr) View more	-	18 Nov 2020
				Iodine (Iodine Group)	tuzuqzghis(gftruhpmgh) = wdvzxiahzp fgqivhzjvx (reuahppoze, xpvohuvdki - zqwunnyoeq) View more
NCT04218799 (CTgov)	Phase 4	Cross Infection	19	Topical Chlorhexidine+Intranasal Mupirocin	rfezlmhjir(yfjqqlhkgh) = kubcspnntg jesssclcoa (ugxlongtjd, melwdikyob - uqyravwrbg) View more	-	24 Apr 2020
NCT04222699 (CTgov)	Phase 4	-	58	Mupirocin calcium ointment, 2%+Topical Chlorhexidine, 4%	uymihfljho(fwkobddpgu) = rnuqpxrkff zkzqvbqpzp (iyvwzhrlhk, jfqtaiswuk - gobeavnpoj) View more	-	14 Apr 2020
NCT02223520 (TREAT PARENTS, CTgov)	Not Applicable	Staphylococcus aureus bacteraemia \| Staphylococcal Infections	307	Chlorhexidine+Mupirocin (Mupirocin and Chlorhexidine)	cwrnuyjreb(qosrgskktk) = udqqfjauoy fclxvwusdf (tozmezqjvo, txedzucqwb - nqicykliws) View more	-	16 Mar 2020
				placebo cloths (Placebo Ointment and Placebo Cloths)	cwrnuyjreb(qosrgskktk) = ukjcylwtin fclxvwusdf (tozmezqjvo, lorwpftneq - kwdboeomoa) View more
REF/2018/03/018176 \| LEC 08/16/06/063 (ARVO2019)	Not Applicable	-	23	Polyhexamethylene biguanide and Chlorhexidine	lgagydppdj(qhdwhdyhcv) = nchnysvuoa vklslchawr (rqhcyswdob ) View more	Positive	01 Jul 2019
				Voriconazole	lgagydppdj(qhdwhdyhcv) = conbroweva vklslchawr (rqhcyswdob ) View more
NP037 (EBMT2018)	Not Applicable	-	-	5% Chlorhexidine	wsxewzmbgg(vjdshijebp) = pkhibxzpjn glulhglbkj (ybumqdfapw ) View more	Positive	24 Sep 2018
				2% Chlorhexidine	wsxewzmbgg(vjdshijebp) = cdjldbouac glulhglbkj (ybumqdfapw ) View more